Klin Farmakol Farm. 2014;28(4):147-151
Vaccination and prevention of pneumococcal community acquired pneumonia
- 1 Klinika pneumológie a ftizeológie LF SZU a UN Bratislava
- 2 Ústav farmakológie a klinickej farmakológie LF UK Bratislava
Pulmonary infections, especially invasive pneumococcal diseases (IPD) are considered as a significant cause of mortality (> 80 %) in
patients with chronic respiratory diseases, mostly in elderly patients over > 70–75 years. The most frequent form of IPD is community
acquired pneumonia (CAP). Clinical experience shows that the best method in terms of preventing and reducing the mortality risk of IPD
and CAP is pneumococcal vaccination. At the present time, adult patients at risk can be vaccinated either with 13-valent pneumococcal
conjugate vaccine (PCV13) or pneumococcal polysaccharide vaccine 23-valent (PPSV23). Both vaccines cover the majority of the Pneumococcus
serotypes involved in CAP pathogenesis. The main advantage of PCV13 is higher awaited protective effect due to its superb
immunogenicity, especially in elderly patients, which is associated with an overall favourable safety profile.
conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine.
Keywords: invasive pneumococcal disease, community acquired pneumonia, pneumococcus, pneumococ13-valent pneumococcal
Published: January 1, 2015 Show citation
